

P17-16. Anti-Langerin-HIV Gag p24 fusion protein targeting Langerhans cells as a new anti-HIV vaccine strategy

Slobodan Culina, Gérard Zurawsky, Anne-Laure Flamar, Pierre Brochard, Benoît Delache, Jacques Banchereau, Roger Le Grand, Frédéric Martinon

► **To cite this version:**

Slobodan Culina, Gérard Zurawsky, Anne-Laure Flamar, Pierre Brochard, Benoît Delache, et al.. P17-16. Anti-Langerin-HIV Gag p24 fusion protein targeting Langerhans cells as a new anti-HIV vaccine strategy. AIDS Vaccine 2009, Oct 2009, Paris, France. BioMed Central, 6 (Suppl 3), pp.P298, 2009, Retrovirology. <10.1186/1742-4690-6-S3-P298>. <inserm-00663928>

HAL Id: inserm-00663928

<http://www.hal.inserm.fr/inserm-00663928>

Submitted on 27 Jan 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Poster presentation

PI7-16. Anti-Langerin-HIV Gag p24 fusion protein targeting Langerhans cells as a new anti-HIV vaccine strategy

S Culina*¹, G Zurawsky², A Flamar², P Brochard¹, B Delache¹, J Banchereau², R Le Grand¹ and F Martinon¹

Address: ¹Institute for Emerging Diseases and Innovative Therapies, DSV, CEA, Division of Immuno-Virology, Fontenay-aux-Roses, France and ²Baylor Institute for Immunology Research INSERM U899, Dallas, TX, USA

* Corresponding author

from AIDS Vaccine 2009
Paris, France. 19–22 October 2009

Published: 22 October 2009

Retrovirology 2009, **6**(Suppl 3):P298 doi:10.1186/1742-4690-6-S3-P298

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P298>

© 2009 Culina et al; licensee BioMed Central Ltd.

Background

Langerhans cells (LC), skin residential cells, are shown to induce specific CD8+ T cell response upon activation. Targeting vaccine antigens to LC with specific antibodies could elucidate specific CD8+ response. Therefore we propose the intra-dermal injection of mAb specific for C-type lectin Langerin, expressed on LC in epidermis, fused to HIV Gag p24 protein, as type of T-cell based vaccine. The present work emphasizes molecular and cellular immune mechanisms triggered in the skin by intra-dermal vaccination.

Methods

Technical approach considers an intra-dermal injection of fusion protein (100 µg) in macaque that was followed by skin and draining lymph nodes (LN) biopsies at different time points. Frozen biopsies were used for immunocytochemistry fluorescent staining to establish biodistribution of injected Ab/fusion protein and co-localisation with different cell types.

Results

We show that antibody used as delivery system, targeted and brought p24 antigen specifically to the LC in epidermis. Number of targeted LC in the zone of injection increased in the first days upon injection and peaked 72 h after injection. In draining LN, HIV Gag p24 were detected as soon as 4 h after injection. 24 h post injection, fusion protein appeared to be associated with CD1a+ cells.

Conclusion

Our data suggested that using viral antigens fused to the mAb specific for LC target and bring viral Ag specifically to this cell population in the zone of injection. This same fusion protein related to the CD1a+ cells was present in draining lymph nodes as soon as 24 h after injection where it could present viral antigen and activate CD8+ T lymphocytes.